Trial Profile
A Randomized, Double-Blind, Placebo-Controlled study to evaluate the effects of Alendronate (ALN) on bone mineral density (BMD) and bone remodeling in perimenopausal women with low BMD
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Nov 2013
Price :
$35
*
At a glance
- Drugs Alendronic acid (Primary)
- Indications Bone resorption; Postmenopausal osteoporosis
- Focus Therapeutic Use
- 14 Nov 2013 New trial record
- 07 Oct 2013 Results presented at the 35th Annual Meeting of the American Society for Bone and Mineral Research.